 This prospective cohort study was performed at the State University of Campinas, Brazil. The Institutional Review Board of the State University of Campinas approved the study and all participants provided informed consent. Female patients with breast cancer who received anthracycline doxorubicin or daunorubicin or epirubicin as part of their chemotherapy protocol were enrolled in the study. 